Update on Clostridium difficile from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, April 22–25, 2017

References

1. • Davies K.
   • Davis G.
   • Barbut F.
   • Eckert C.
   • Petrosillo N.
   • Pisapia R.
   • et al.
   Multivariate analysis of factors affecting Clostridium difficile infection rates; the more you look, the more you find, but should you believe what you see?.
   in: ECCMID. 2017 (Abstract OS0221)
   View in Article

   • Google Scholar
2. • Eyre D.W.
   • Davies K.
   • Davis G.
   • Fawley W.
   • Karas A.
   • Crook D.W.
   • et al.
   Clostridium difficile diversity across Europe from whole-genome sequencing.
   in: ECCMID. 2017 (Abstract OS0227)
   View in Article

   • Google Scholar
3. • Leonard A.
   • Robertson C.
   • Pan J.
   • Ford I.
   • McCowan C.
   • Walker A.
   • et al.
   Clinical outcomes following hospitalization with Clostridium difficile.
   in: ECCMID. 2017 (Abstract OS0224)
   View in Article

   • Google Scholar
4. • Enoch D.A.
   • Murray-Thomas T.
   • Dedman D.
   • Tretter R.
   • Adomakoh N.
   • Karas A.
   • et al.
   Retrospective cohort study of the risk of complications and all-cause mortality in adults with hospital-associated recurrent Clostridium difficile infection in England.
   in: ECCMID. 2017 (e-poster EPO181)
   View in Article

   • Google Scholar
5. • Rahav G.
   • Yacyshyn B.
   • Kao D.
   • Ellison M.C.
   • Pedley A.
   • Eves K.
   • et al.
   Efficacy of bezlotoxumab in patients with recurrent Clostridium difficile infection: pooled analysis of data from the MODIFY trials.
   in: ECCMID. 2017 (Abstract P2048)
   View in Article

   • Google Scholar
6. • Trucksis M.
   • Baird I.
   • Cornely O.A.
   • Golan Y.
   • Hecht G.
   • Pardi D.S.
   • et al.
   An analysis of results from the first placebo-controlled trial of single-dose SER-109, an investigational oral microbiome therapeutic to reduce the recurrence of Clostridium difficile infection (CDI).
   in: ECCMID. 2017 (Abstract OS0250)
   View in Article

   • Google Scholar
7. • Thorpe C.
   • Kane A.
   • Change J.
   • Vickers R.
   • Snydman D.R.
   Ridinilazole treatment for C. difficile infection preserves the intestinal microbiota of patients.
   in: ECCMID. 2017 (Abstract P2049)
   View in Article

   • Google Scholar